PMID- 16081585
OWN - NLM
STAT- MEDLINE
DCOM- 20061221
LR  - 20211203
IS  - 0091-7370 (Print)
IS  - 0091-7370 (Linking)
VI  - 35
IP  - 3
DP  - 2005 Summer
TI  - Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent 
      asthma treated with montelukast: a 16-week single-blind randomized study.
PG  - 285-9
AB  - Pharmacological therapy with inhaled steroids (IS) is currently considered the 
      gold-standard of treatment for mild-persistent asthma. Leukotriene receptor 
      antagonist drugs (LTRAs) play an important role associated with IS, allowing dose 
      tapering and maintaining control of asthma symptoms. The aim of this study was to 
      determine the effectiveness of montelukast (MON) to allow tapering of the inhaled 
      dose of budesonide (BUD) in patients with mild-moderate persistent asthma. This 
      16-wk single-blind randomized study included 40 asthmatic patients divided in 2 
      treatment groups. After a run-in period (4 wk), in which all patients inhaled 400 
      microg of BUD twice daily (bid), group A (20 patients) received MON (oral, 10 
      mg/day) combined with inhaled BUD (400 microg/bid), while group B (20 patients) 
      was treated with BUD for the whole period of the study. In both groups, at every 
      4 wk the dose of BUD was halved. After 12 wk of treatment the mean value of 
      forced expiratory volume during the first sec (FEV1, as % of predicted value) was 
      significantly greater in group A compared with group B (94 +/- 7.5 vs 83.1 +/- 
      6.9; p<0.005). The mean values of peak expiratory flow (PEF), the percentages of 
      asthmatic exacerbations, and the use of beta2-short-acting agonist (SABA) were 
      similar in the 2 groups at 4, 8, and 12 wk. In conclusion, in patients with 
      mild-moderate persistent asthma, MON therapy is useful in tapering the dose of IS 
      in order to reduce its side effects and to maintain the clinical stability of the 
      disease.
FAU - Riccioni, Graziano
AU  - Riccioni G
AD  - Department of Biomedical Sciences, University of G. D'Annunzio, Chieti, Italy. 
      griccioni@hotmail.com
FAU - Vecchia, Rosanna Della
AU  - Vecchia RD
FAU - Castronuovo, Marco
AU  - Castronuovo M
FAU - Di Ilio, Carmine
AU  - Di Ilio C
FAU - D'Orazio, Nicolantonio
AU  - D'Orazio N
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 51333-22-3 (Budesonide)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Asthma/*drug therapy
MH  - Budesonide/*administration & dosage/*therapeutic use
MH  - Cyclopropanes
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quinolines/*therapeutic use
MH  - Respiratory Function Tests
MH  - Single-Blind Method
MH  - Sulfides
MH  - Time Factors
EDAT- 2005/08/06 09:00
MHDA- 2006/12/22 09:00
CRDT- 2005/08/06 09:00
PHST- 2005/08/06 09:00 [pubmed]
PHST- 2006/12/22 09:00 [medline]
PHST- 2005/08/06 09:00 [entrez]
AID - 35/3/285 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2005 Summer;35(3):285-9.